Nonsteroidal MRAs in patients with CKD and T2D: What is next for finerenone?

Bayer AG |

Chair: Samy Hadjadj (FRA)

18:30 – 18:35Welcome and introductionsSamy Hadjadj (FRA)
18:35 – 19:00Optimising treatment of CKD associated with T2D: Time for a combination therapy approach?Hiddo Heerspink (NLD)
19:00 – 19:10Nonsteroidal MRAs beyond CKD in T2D: New paths to uncoverPaola Fioretto (ITA)
19:10 – 19:20Finerenone in routine clinical practice: Looking beyond the data from pivotal trialsChristoph Wanner (GER)
19:20 – 19:30Q&A and closeSamy Hadjadj (FRA)